Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population
Key facts
- Where
- Rome, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT06992986, who can take part
Where in Italy
- Regina Elena National Cancer InstituteRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regina Elena Cancer Institute
- Trial code
- NCT06992986
- Record updated
- 28 May 2025
- Original description
The study aims to investigate alterations in the bladder microbiome in adult men with bladder cancer, healthy men, and men with benign urinary diseaseRead full original descriptionShow less
Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterpars Adult Male Population: a Pilot Study
The study aims to investigate alterations in the bladder microbiome in adult men with bladder cancer, healthy men, and men with benign urinary disease
Inclusion: Diagnosis of bladder cancer; Negative urine culture; Histological confirmation of urothelial carcinoma; Patients undergoing radical cystectomy; Controls will be collected from men within the specified age range. Eligible controls may be drawn from the institution's personnel attending the occupational medicine department or in service in the Institute; -To ensure that alterations in the microbiome observed in bladder cancer patients are unique to this condition, an additional group with benign urinary diseases will be included in the analysis. This group will encompass individuals with renal cysts, benign prostatic obstruction, ureteropelvic or ureteral obstruction undergoing surgical therapy.
Exclusion: History of previous BCG therapy; Active antibiotic treatment with two months prior to participation; Previous neoadyuvant therapy; History of sexual transmitted diseases; Diabetes; Chronic Kidney Disease; Cardiac disease; Hepatic disease; Presence of other neoplasias; Use of indwelling catheter; Presence of chronic intestinal inflammation; NA.